820 related articles for article (PubMed ID: 23562768)
1. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
3. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM
Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157
[TBL] [Abstract][Full Text] [Related]
4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
Chang DT; Schellenberg D; Shen J; Kim J; Goodman KA; Fisher GA; Ford JM; Desser T; Quon A; Koong AC
Cancer; 2009 Feb; 115(3):665-72. PubMed ID: 19117351
[TBL] [Abstract][Full Text] [Related]
6. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiation therapy boost in locally advanced pancreatic cancer.
Seo Y; Kim MS; Yoo S; Cho C; Yang K; Yoo H; Choi C; Lee D; Kim J; Kim MS; Kang H; Kim Y
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1456-61. PubMed ID: 19783379
[TBL] [Abstract][Full Text] [Related]
9. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
[TBL] [Abstract][Full Text] [Related]
11. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.
Chapman BC; Gleisner A; Rigg D; Meguid C; Goodman K; Brauer B; Gajdos C; Schulick RD; Edil BH; McCarter MD
J Surg Oncol; 2018 Apr; 117(5):1073-1083. PubMed ID: 29448308
[TBL] [Abstract][Full Text] [Related]
12. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
14. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
Huang WY; Jen YM; Lee MS; Chang LP; Chen CM; Ko KH; Lin KT; Lin JC; Chao HL; Lin CS; Su YF; Fan CY; Chang YW
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):355-61. PubMed ID: 22342300
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Shaib WL; Hawk N; Cassidy RJ; Chen Z; Zhang C; Brutcher E; Kooby D; Maithel SK; Sarmiento JM; Landry J; El-Rayes BF
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):296-303. PubMed ID: 27475674
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.
Hill CS; Rosati LM; Hu C; Fu W; Sehgal S; Hacker-Prietz A; Wolfgang CL; Weiss MJ; Burkhart RA; Hruban RH; De Jesus-Acosta A; Le DT; Zheng L; Laheru DA; He J; Narang AK; Herman JM
Ann Surg Oncol; 2022 Apr; 29(4):2456-2468. PubMed ID: 35129721
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
Andolino DL; Johnson CS; Maluccio M; Kwo P; Tector AJ; Zook J; Johnstone PA; Cardenes HR
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e447-53. PubMed ID: 21645977
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative radiotherapy for pancreatic cancer: 30-year experience in a single institution in Japan.
Jingu K; Tanabe T; Nemoto K; Ariga H; Umezawa R; Ogawa Y; Takeda K; Koto M; Sugawara T; Kubozono M; Shimizu E; Abe K; Yamada S
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e507-11. PubMed ID: 22445002
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
